FDA Warns Of High Mortality Rate For Medtronic Stent

Law360, New York (March 19, 2008, 12:00 AM EDT) -- Patients using Medtronic Inc.'s AneuRx stent graft system have a higher mortality rate than previously thought, the U.S. Food and Drug Administration announced this week.

In a statement posted on its Web site, the FDA wrote that the per-year mortality risk in patients receiving the stent continues to increase for years after the device is implanted.

The mortality rate is also significantly higher for patients who have the stent than for patients who have surgery, the FDA said.

Earlier research had suggested that aneurysm-related mortality was...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.